132 related articles for article (PubMed ID: 8845569)
21. The regulatory mechanism of IL-6-dependent proliferation of human myeloma cells.
Tsuyama N; Ishikawa H; Abroun S; Liu S; Li FJ; Otsuyama K; Zheng X; Obata M; Taniguchi O; Kawano MM
Hematology; 2003 Dec; 8(6):409-11. PubMed ID: 14668037
[TBL] [Abstract][Full Text] [Related]
22. Cytokine network in human multiple myeloma.
Klein B; Bataille R
Hematol Oncol Clin North Am; 1992 Apr; 6(2):273-84. PubMed ID: 1582974
[TBL] [Abstract][Full Text] [Related]
23. Plasma cell myeloma--new biological insights and advances in therapy.
Barlogie B; Epstein J; Selvanayagam P; Alexanian R
Blood; 1989 Mar; 73(4):865-79. PubMed ID: 2465790
[TBL] [Abstract][Full Text] [Related]
24. Requirement of soluble factors produced by bone marrow stromal cells on the growth of novel established human myeloma cell line.
Aikawa S; Hatta Y; Tanaka M; Kaneita Y; Yasukawa K; Sawada U; Horie T; Tsuboi I; Aizawa S
Int J Oncol; 2003 Mar; 22(3):631-7. PubMed ID: 12579318
[TBL] [Abstract][Full Text] [Related]
25. Functional granulocyte/macrophage colony stimulating factor receptor is constitutively expressed on neoplastic plasma cells and mediates tumour cell longevity.
Villunger A; Egle A; Kos M; Egle D; Tinhofer I; Henn T; Uberall F; Maly K; Greil R
Br J Haematol; 1998 Sep; 102(4):1069-80. PubMed ID: 9734660
[TBL] [Abstract][Full Text] [Related]
26. Molecular and biological characterization of three novel interleukin-6-dependent human myeloma cell lines.
Verdelli D; Mattioli M; Fabris S; Nobili L; Intini D; Guerneri S; Todoerti K; Zanella A; Deliliers GL; Lombardi L; Neri A
Haematologica; 2005 Nov; 90(11):1541-8. PubMed ID: 16266902
[TBL] [Abstract][Full Text] [Related]
27. Dissection of the signalling requirements of interleukin-6-stimulated myeloma cell growth.
French JD; Tschumper RC; Jelinek DF
Acta Oncol; 2000; 39(7):777-81. PubMed ID: 11145432
[TBL] [Abstract][Full Text] [Related]
28. Both CD28 ligands CD80 (B7-1) and CD86 (B7-2) activate phosphatidylinositol 3-kinase, and wortmannin reveals heterogeneity in the regulation of T cell IL-2 secretion.
Ueda Y; Levine BL; Huang ML; Freeman GJ; Nadler LM; June CH; Ward SG
Int Immunol; 1995 Jun; 7(6):957-66. PubMed ID: 7577804
[TBL] [Abstract][Full Text] [Related]
29. Maturation of neonatal human CD4 T cells: III. Role of B7 co-stimulation at priming.
Yang LP; Demeure CE; Byun DG; Vezzio N; Delespesse G
Int Immunol; 1995 Dec; 7(12):1987-93. PubMed ID: 8746568
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of inhibition of IL-6-mediated immunoglobulin secretion by dexamethasone and suramin in human lymphoid and myeloma cell lines.
Shiao RT; McLeskey SB; Khera SY; Wolfson A; Freter CE
Leuk Lymphoma; 1996 Apr; 21(3-4):293-303. PubMed ID: 8726410
[TBL] [Abstract][Full Text] [Related]
31. Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin 6-mediated up-regulation of bcl-xL.
Schwarze MM; Hawley RG
Cancer Res; 1995 Jun; 55(11):2262-5. PubMed ID: 7757973
[TBL] [Abstract][Full Text] [Related]
32. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-6 sensitizes multiple myeloma cell lines for apoptosis induced by interferon-alpha.
Minami R; Muta K; Ilseung C; Abe Y; Nishimura J; Nawata H
Exp Hematol; 2000 Mar; 28(3):244-55. PubMed ID: 10720689
[TBL] [Abstract][Full Text] [Related]
34. Defective B7 expression on antigen-presenting cells underlying T cell activation abnormalities in systemic lupus erythematosus (SLE) patients.
García-Cózar FJ; Molina IJ; Cuadrado MJ; Marubayashi M; Peña J; Santamaría M
Clin Exp Immunol; 1996 Apr; 104(1):72-9. PubMed ID: 8603537
[TBL] [Abstract][Full Text] [Related]
35. Drug resistance in multiple myeloma: novel therapeutic targets within the malignant clone.
Pilarski LM; Mant MJ; Belch AR
Leuk Lymphoma; 1999 Jan; 32(3-4):199-210. PubMed ID: 10037018
[TBL] [Abstract][Full Text] [Related]
36. The role of interleukin-6 and interleukin-6/interleukin-6 receptor-alpha complex in the pathogenesis of multiple myeloma.
Barillé S; Bataille R; Amiot M
Eur Cytokine Netw; 2000 Dec; 11(4):546-51. PubMed ID: 11125296
[TBL] [Abstract][Full Text] [Related]
37. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma.
Klein B; Zhang XG; Jourdan M; Boiron JM; Portier M; Lu ZY; Wijdenes J; Brochier J; Bataille R
Eur Cytokine Netw; 1990; 1(4):193-201. PubMed ID: 2104241
[TBL] [Abstract][Full Text] [Related]
38. Interleukin-6-induced proliferation of human myeloma cells associated with CD45 molecules.
Ishikawa H; Tsuyama N; Kawano MM
Int J Hematol; 2003 Aug; 78(2):95-105. PubMed ID: 12953802
[TBL] [Abstract][Full Text] [Related]
39. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
Lauta VM
Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
[TBL] [Abstract][Full Text] [Related]
40. C-kit ligand (SCF) in human multiple myeloma cells.
Lemoli RM; Fortuna A
Leuk Lymphoma; 1996 Feb; 20(5-6):457-64. PubMed ID: 8833403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
